The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Anxiety in Parkinson's disease: identification and management
Open accessAbstract
Anxiety disturbances are recognized as common psychiatric comorbidities in Parkinson’s disease (PD) and contribute to significant impairments in areas of cognitive, functional, motor and social performance. Anxiety in PD results in reduced quality of life, higher levels of care dependency and increased caregiver burden. Surprisingly, there is a paucity of treatment data. In one randomized, controlled study, bromazepam was found to be effective for anxiety in PD. However, usage of benzodiazepines in the PD population is limited by potential risk of confusion and falls. There are no controlled studies of selective serotonin reuptake inhibitors (SSRIs) for anxiety in PD. However, results from uncontrolled studies suggest that SSRIs are effective for anxiety in PD, although in these studies anxiety outcomes were secondary. This review underscores that, given the high prevalence of anxiety disturbances in PD, there is a significant paucity of treatment data for this population. Additional studies are warranted. In the meantime, clinicians should rely on empiric assessments of known risks and putative benefits to guide treatment decisions. Cognitive and behavioral therapies (with or without pharmacotherapy) have demonstrated efficacy and warrant consideration. When feasible, a targeted and individualized multimodal approach utilizing psychotherapeutic interventions along with pharmacologic therapies should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“concerns regarding unfavorable side effects, including exacerbation of motor problems in patients with complex medication regimes, have been noted (Rabinstein and Shulman, 2000”
From Remote delivery of psychological interventions for Parkinson's disease. (2018) · cites this paper as Chen and Marsh, 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Rémy, P., Doder, M., Lees, A. J., Turjanski, N., & Brooks, D. J. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,090
Drug Facts and Comparisons 1991.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-823_1 · Cited by 776
Non-recognition of depression and other non-motor symptoms in Parkinson's disease
Shulman, L. M., Taback, R. L., Rabinstein, A. A., & Weiner, W. J. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00015-3 · Cited by 695
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642
Factors impacting on quality of life in Parkinson's disease: Results from an international survey
The Global Parkinson's Disease Survey (GPDS) Steering Committee (2002) · Movement Disorders · doi:10.1002/mds.10010 · Cited by 524
Gallagher, D. A., Lees, A. J., & Schrag, A. E. (2010) · Movement Disorders · doi:10.1002/mds.23394 · Cited by 506
Research works printed but not linked: 6
- Black K., 2000, J Psychiatry Neurosci, 25, 255
- Casacchia M., 1975, Riv Neurol, 45, 326
- Hanna K., 2012, Parkinsons Dis, 2012, 640707
- Kano O., 2011, Parkinsons Dis, 2011, 143547
- Richard I., 2004, Cogn Behav Neurol, 17, 201
- Shulman L., 1996, Mov Disord, 11, 12
Cited by
Sorted by citations
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 557
van Uem, J. M. T., Marinus, J., Canning, C. G., van Lummel, R. C., Dodel, R. C., Liepelt‐Scarfone, I., Berg, D., Morris, M. E., & Maetzler, W. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.014 · Cited by 218
Reynolds, G., Otto, M. W., Ellis, T. D., & Cronin‐Golomb, A. (2015) · Movement Disorders · doi:10.1002/mds.26484 · Cited by 144
The clinical spectrum of anxiety in Parkinson's disease
Dissanayaka, N. N. N. W., White, E., O'Sullivan, J. D., Marsh, R., Pachana, N. A., & Byrne, G. J. (2014) · Movement Disorders · doi:10.1002/mds.25937 · Cited by 124
Psychiatric Manifestation in Patients with Parkinson's Disease
Han, J. W., Ahn, Y. D., Kim, W.-S., Shin, C. M., Jeong, S. J., Song, Y. S., Bae, Y. J., & Kim, J.-M. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e300 · Cited by 127
Metadata
- Authors
- Chen, J. J., & Marsh, L.
- Affiliations
- Loma Linda University (US)
- Michael E. DeBakey VA Medical Center (US)
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2013-07-17
- Volume
- 7
- Issue
- 1
- Pages
- 52-59
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC3886380
- OpenAlex
- W2149341227
- Cited by
- 161
- References
- 69
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 18 · 2023: 10 · 2022: 17 · 2021: 20 · 2020: 15 · 2019: 15 · 2018: 7 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 5
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, anxiety, psychiatric comorbidity, benzodiazepines, bromazepam, selective serotonin reuptake inhibitors, multimodal therapy, quality of life, caregiver burden, fall risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
